Park Medi World IPO Allotment Live: Check application status, allotment odds, GMP and listing update

Established in 2011, New Delhi-headquartered Park Medi World operates a private hospital chain with a strong presence in North India. The company manages 14 multi super-speciality hospitals under the 'Park' brand, with an aggregate capacity of around 3,000 beds. Its footprint covers Haryana, Delhi, Punjab and Rajasthan, providing over 30 super-speciality and speciality healthcare services.

As per the prospectus, the registrar, being a SEBI-registered entity, is responsible for:

Electronically processing all applications

Conducting the allotment process

Ensuring timely credit of shares to successful applicants

Dispatching and uploading refunds

Addressing all investor-related queries

Investors can also check their allotment status on KFin Technologies Limited portal: https://kosmic.kfintech.com/ipostatus

Steps to check:

Go to the web portal of KFin Technologies Limited

Select the IPO from the dropdown menu (appears only if allotment is finalized)

Choose one of the three modes: Application Number, Demat Account Number, or PAN ID

Select the application type: ASBA or non-ASBA

Enter the details for the mode selected in Step 3

Fill in the captcha accurately for security

Click Submit

Under Issue Type, select Equity

Under Issue Name, select Park Medi World Limited

Enter your application number

Enter your PAN card ID

Verify by clicking "I am not a Robot" and hit Search

Investors can check their allotment status on the Bombay Stock Exchange (BSE) website by following these steps:

Refund initiations and credit of shares are expected by Tuesday, December 16. The shares of Park Medi World will be listed on both BSE and NSE on December 17, 2025.

The book running lead managers (BRLMs) for the IPO are Nuvama Wealth Management, CLSA India, DAM Capital Advisors, and Intensive Fiscal Services. KFin Technologies is appointed as the registrar of the issue, responsible for processing applications, carrying out allotment, and updating electronic credits of shares to successful applicants.

Incorporated in 2011, New Delhi-based Park Medi World is a private hospital chain primarily operating in North India. The company has a total bed capacity of 3,000 beds and runs 14 multi-super speciality hospitals under the 'Park' brand. Its network spans Haryana, Delhi, Punjab, and Rajasthan, offering more than 30 super speciality and speciality services.

The grey market premium (GMP) has moderated due to muted bids and volatile market sentiment. Last heard, the GMP was around Rs 6-7, suggesting a listing gain of approximately 4%. During the bidding period, the GMP had ranged between Rs 7-8.

Based on the subscription, the allotment probability for different categories is as follows:

Big HNI category: 2 investors out of 7 will receive 1,288 shares (28.57% probability)

Small HNI category: 1 investor out of 11 will receive 1,288 shares (9.09% probability)

Retail category: 1 investor out of 3 will get 92 shares (33.33% probability)

The issue was subscribed 8.10 times overall, attracting bids worth nearly Rs 5,500 crore from over 6.45 lakh applications. Qualified institutional buyers (QIBs) subscribed 11.48 times, the non-institutional investors (NIIs) portion saw 15.15 times subscription, and the retail category was subscribed 3.16 times.

The IPO was open for subscription between December 10 and December 12, with shares offered in a price band of Rs 154-162 per share and a lot size of 92 shares. The issue raised a total of Rs 920 crore, including fresh shares worth Rs 770 crore (4,75,30,864 shares) and an offer-for-sale (OFS) of Rs 150 crore (92,59,259 shares).

Park Medi World is expected to finalise the basis of allotment of its shares today, December 15. Applicants will receive messages, alerts, or emails regarding the debit of funds or revocation of IPO mandates by Tuesday, December 16. The private hospital chain received a decent response from investors during its three-day bidding period.

The red herring prospectus (RHP) notes that 75.11% of domestic sales are generated from urban and semi-urban areas, supported by a network of 2,671 medical representatives. The company has improved its market rank from 37th in MAT June 2022 to 29th in MAT June 2025.

Shares of Corona Remedies (CORONA | 544644 | INE02ZQ01018) are currently trading at Rs 1,473.95, up Rs 21.95 (1.51%) on the day. Since listing, the stock has surged Rs 411.95, or 38.79%, over its IPO price, reflecting strong investor demand and market confidence in the company's business and growth prospects.

Longer-term returns for investors will depend on Corona Remedies' ability to maintain margins, expand its brand portfolio, and manage pricing pressures in India's competitive pharmaceutical market. (Read More)

Corona Remedies made a healthy stock market debut to list at more than 38 percent premium over its initial public offering (IPO) price on the National Stock Exchange (NSE), following a massive subscription of 137.04 times between December 8-10 in the primary market. Shares of Corona Remedies were listed at Rs 1,470 per share on the NSE, a decent premium of 38.42 percent. The Rs 655.37-crore issue had a price band of Rs 1,008-1,062 per share. (Read More)

Shares of Corona Remedies made a strong start on Dalal Street, listing at a 38.42 per cent premium over the IPO price. The stock opened at Rs 1,470 on the NSE and Rs 1,452 on the BSE, compared with the issue price of Rs 1,062.

As outlined in the red herring prospectus (RHP), the company's operating cash flow to EBITDA ratio stood at 77.46 per cent in FY2025, reflecting strong cash conversion efficiency.

The red herring prospectus (RHP) highlights that India's GDP expanded 7 per cent in FY2023, outpacing both advanced and emerging economies. The growth momentum is expected to continue, supported by favourable demographics, rising consumption, and global supply chain realignment.

As outlined in the red herring prospectus (RHP), global healthcare expenditure accounted for around 10 per cent of GDP in 2022, while India's healthcare spending stood at 3.3 per cent of GDP, highlighting the significant growth potential of the Indian healthcare market.

The RHP highlights that retail pharmaceuticals accounted for nearly one-sixth of healthcare expenditure in OECD countries in 2021, with India's pharmaceutical spending at 21% of healthcare expenditure as of 2020.

As per the RHP, the Indian domestic formulation market, valued at around Rs 2.3 trillion in FY 2025, is projected to expand to Rs 3.3-3.5 trillion by FY 2030, supported by a rise in chronic diseases and improved access to healthcare.

The Rs 655.68 crore public issue was structured entirely as an offer for sale (OFS) of 0.62 crore shares. Under the OFS, promoters Dr Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Brinda Ankur Mehta, and Dipabahen Niravkumar Mehta are divesting part of their holdings.

In addition, investors Sage Investment Trust, Sepia Investments, and Anchor Partners are also offloading their stakes.

Explaining the rationale for the listing, the company said in its red herring prospectus that it expects the equity shares' listing to enhance brand visibility and provide liquidity to existing shareholders, while also creating a public market for its shares in India.

Click on this link to watch the listing ceremony live - https://x.com/i/broadcasts/1lPJqvdqaRdxb

Corona Remedies Ltd (CORONA | 544644 | INE02ZQ01018) is seeing its pre-open session ahead of its stock market debut, with the indicative price currently at Rs 1,062.00. No movement has been recorded yet, with a 0.00% change in price and quantity. The indicative quantity in the pre-open session stands at 6,133 shares, reflecting early market interest as investors position themselves ahead of the IPO listing.

This pre-open price provides an initial indication of investor sentiment and expected demand as the stock prepares to start trading.

Corona Remedies IPO last GMP is Rs 342.5, last updated Dec 15th 2025 07:57 AM, as per Investorgain.com With the price band of 1062.00, Corona Remedies IPO's estimated listing price is Rs 1404.5 (cap price + today's GMP).The expected percentage gain/loss per share is 32.25%.

Wakefit, Corona Remedies, Dr Reddys Labs, Wipro, Aurobindo Pharma, NLC India, Ashoka Buildcon, KEC in focus on 15 December (Read More)

As of December 2024, the company had a diversified portfolio of 67 brands catering to multiple therapeutic areas.

Headquartered in Ahmedabad, Corona Remedies is a pharmaceutical formulation company involved in the development, manufacturing and marketing of products across women's healthcare, cardio-diabetes, pain management, urology and other therapeutic segments.

Under the OFS route, promoters along with existing investors, including Sepia Investments, Anchor Partners and Sage Investment Trust, are proposing to sell their shares in the public issue.

The company's IPO is entirely structured as an offer for sale (OFS) by its promoters and existing investors.

The Corona Remedies IPO was a book-built issue comprising a complete offer for sale (OFS) of shares with a face value of Rs 10 each, aggregating to Rs 655.37 crore. The issue opened for subscription on December 8, 2025, closed on December 10, 2025, and the share allotment was finalised on December 11, 2025.

Retail investors subscribed 28.73 times the issue, placing bids for 6,48,02,038 shares against the 22,55,281 shares allocated to the category.

Non-Institutional Investors (NIIs) followed closely, subscribing 208.88 times, with bids for 20,18,97,066 shares compared with 9,66,549 shares available in the segment.

Qualified Institutional Buyers (QIBs) emerged as the biggest contributors, subscribing 278.52 times their allotted quota by bidding for 35,89,39,448 shares against 12,88,732 shares reserved for the category.

According to data from the BSE, the issue received bids for 62,65,41,440 shares against 45,71,882 shares on offer by the close of the bidding period, translating into an overall subscription of 137.04 times.

Shivani Nyati, Head of Wealth at Swastika Investmart Ltd, expects the IPO to deliver a healthy listing premium of around 25-27 per cent, with an estimated listing price in the range of Rs 1,330 to Rs 1,350 per share.

Grey market premium is an unofficial indicator that reflects investor appetite for a primary market issue ahead of its listing on the stock exchanges.

As of December 14, 2025, the grey market premium (GMP) for the Corona Remedies IPO stood at Rs 295 per share. With the upper price band fixed at Rs 1,062, the stock is expected to list around Rs 1,357 per share, suggesting a potential listing gain of nearly 28 per cent, according to IPO India data.

Headquartered in Gujarat, Corona Remedies is a pharmaceutical company engaged in the development and manufacturing of medicines, with a key focus on women's healthcare, cardio-diabetes and other therapeutic areas.

The IPO attracted robust investor interest during its three-day bidding window, with the issue being oversubscribed 137.04 times the shares on offer across investor categories.

Hello and welcome to Moneycontrol. Corona Remedies' initial public offering (IPO) is scheduled to be listed on the Indian stock exchanges today, December 15, 2025, with grey market trends indicating a strong debut.